Status:
COMPLETED
B-CD30 + Hodgkin Lymphoma International Multi-center Retrospective Study of Treatment Practices and Outcomes
Lead Sponsor:
Takeda
Conditions:
Classical Hodgkin Lymphoma
Relapsed or Refractory Classical Hodgkin Lymphoma
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to describe progression-free survival (PFS) in participants with relapsed or refractory classical Hodgkin lymphoma (RRHL), defined as the time from initiation of first tre...
Detailed Description
This is a retrospective, non-interventional study of participants with newly-diagnosed cHL, or with RRHL. The study will review the medical records of participants to describe participant's demographi...
Eligibility Criteria
Inclusion
- Participants newly diagnosed with high-risk stage IIb-IV cHL (for Group 1) or RRHL (for Group 2) between 01 January 2010 and 31 December 2013.
- Age greater than or equal to (\>=) 18 years at diagnosis of cHL (Group 1) or RRHL (Group 2).
- Alive or deceased.
- Written informed consent is obtained for study data collection, where necessary, according to local regulations.
Exclusion
- Participants for whom the minimum study dataset is not available from their hospital medical records.
- Participants who have participated in an interventional clinical trial at any stage of their cHL (Group 1) or RRHL (Group 2) management.
Key Trial Info
Start Date :
November 21 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 31 2019
Estimated Enrollment :
1770 Patients enrolled
Trial Details
Trial ID
NCT03327571
Start Date
November 21 2017
End Date
October 31 2019
Last Update
June 25 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pusan National University Hospital
Busan, South Korea, 49241